Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mepuzapine
- Development stage
- Unknown
- Lead developer
- Venturepharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mepuzapine (VPC-14) is a novel small molecule analgesic developed by Beijing Dezhong Wanquan Pharmaceutical Technology (Venturepharm). Chemically a dibenzo[b,e][1,4]diazepine derivative, it is being investigated as a centrally acting, non-opioid treatment for moderate to acute pain. The drug is designed to offer potent analgesia without the addiction liability or respiratory depression typically associated with opioid medications. Clinical development has primarily occurred in China, where it has undergone Phase 1 pharmacokinetic evaluation in healthy volunteers to characterize its plasma concentration–time profile and safety.
- Other names
- mepuzapine hydrochloride美普扎平
Beyond the preview
Go deeper on mepuzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mepuzapine.